Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions
Highlights • Neurological diseases increasing in incidence but lack effective treatment. • Complement activation linked to the majority of neurological diseases. • Inhibition of complement generally protective in neurological disease models. • Therapies must balance protective and pathogenic sequela...
Gespeichert in:
| Veröffentlicht in: | Seminars in immunology 2016-06, Vol.28 (3), p.292-308 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 308 |
|---|---|
| container_issue | 3 |
| container_start_page | 292 |
| container_title | Seminars in immunology |
| container_volume | 28 |
| creator | Brennan, Faith H Lee, John D Ruitenberg, Marc J Woodruff, Trent M |
| description | Highlights • Neurological diseases increasing in incidence but lack effective treatment. • Complement activation linked to the majority of neurological diseases. • Inhibition of complement generally protective in neurological disease models. • Therapies must balance protective and pathogenic sequela of complement activation. • Complement inhibitors show promise as future candidates for clinical trials. |
| doi_str_mv | 10.1016/j.smim.2016.03.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811842391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1044532316000221</els_id><sourcerecordid>1811842391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-a00e96185cabaaeed55635b2cbac627016b5819f8fd330c54047a78be1f960e73</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhhtR3A_9Ax4kRy_dpvLR0w0iyKKusODB9RzSSfWYsZOMSXph_r1pZvXgwVMV1PsWVc_bNK-AdkChf3vosne-Y7XvKO8oyCfNJdCxb3kPw9OtF6KVnPGL5irnA6WUiwGeNxdsR8Uo5HjZLPc_MOkjrsUZUnTaY3FhT-JMTPTHBT2GQkokPlo3n4h1GXXGOlxTLTpY4vwxxQckcS3Vgpm4QAKuKS5x74xeqjZYV1wM-UXzbNZLxpeP9br5_unj_c1te_f185ebD3etEQCl1ZTiWD-QRk9aI1opey4nZiZt-no69JMcYJyH2XJOjRRU7PRumBDmsae449fNm_PeetmvFXNR3mWDy6IDxjUrGAAGwfgIVcrOUpNizglndUzO63RSQNVGWR3URlltlBXlqlKupteP-9fJo_1r-YO1Ct6dBVi_fHCYVDYOg0HrEpqibHT_3__-H7tZXNhg_sQT5kOFHyo_BSozRdW3LectZuhrxIwB_w1wb6Ui</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811842391</pqid></control><display><type>article</type><title>Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Brennan, Faith H ; Lee, John D ; Ruitenberg, Marc J ; Woodruff, Trent M</creator><creatorcontrib>Brennan, Faith H ; Lee, John D ; Ruitenberg, Marc J ; Woodruff, Trent M</creatorcontrib><description>Highlights • Neurological diseases increasing in incidence but lack effective treatment. • Complement activation linked to the majority of neurological diseases. • Inhibition of complement generally protective in neurological disease models. • Therapies must balance protective and pathogenic sequela of complement activation. • Complement inhibitors show promise as future candidates for clinical trials.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2016.03.015</identifier><identifier>PMID: 27049459</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Brain - pathology ; C5a ; Clinical Trials as Topic ; Complement ; Complement Activation ; Complement Inactivating Agents - therapeutic use ; Complement System Proteins - metabolism ; Disease Progression ; Humans ; Molecular Targeted Therapy ; Neurodegeneration ; Neurodegenerative Diseases - immunology ; Neurodegenerative Diseases - therapy ; Neuroprotection ; Neurotrauma ; Stroke ; Therapeutics ; Treatment Outcome ; Wounds and Injuries - immunology ; Wounds and Injuries - therapy</subject><ispartof>Seminars in immunology, 2016-06, Vol.28 (3), p.292-308</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-a00e96185cabaaeed55635b2cbac627016b5819f8fd330c54047a78be1f960e73</citedby><cites>FETCH-LOGICAL-c411t-a00e96185cabaaeed55635b2cbac627016b5819f8fd330c54047a78be1f960e73</cites><orcidid>0000-0003-1382-911X ; 0000-0002-9201-2476 ; 0000-0002-9976-7396 ; 0000-0002-6917-0708</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1044532316000221$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27049459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brennan, Faith H</creatorcontrib><creatorcontrib>Lee, John D</creatorcontrib><creatorcontrib>Ruitenberg, Marc J</creatorcontrib><creatorcontrib>Woodruff, Trent M</creatorcontrib><title>Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>Highlights • Neurological diseases increasing in incidence but lack effective treatment. • Complement activation linked to the majority of neurological diseases. • Inhibition of complement generally protective in neurological disease models. • Therapies must balance protective and pathogenic sequela of complement activation. • Complement inhibitors show promise as future candidates for clinical trials.</description><subject>Allergy and Immunology</subject><subject>Brain - pathology</subject><subject>C5a</subject><subject>Clinical Trials as Topic</subject><subject>Complement</subject><subject>Complement Activation</subject><subject>Complement Inactivating Agents - therapeutic use</subject><subject>Complement System Proteins - metabolism</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative Diseases - immunology</subject><subject>Neurodegenerative Diseases - therapy</subject><subject>Neuroprotection</subject><subject>Neurotrauma</subject><subject>Stroke</subject><subject>Therapeutics</subject><subject>Treatment Outcome</subject><subject>Wounds and Injuries - immunology</subject><subject>Wounds and Injuries - therapy</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhhtR3A_9Ax4kRy_dpvLR0w0iyKKusODB9RzSSfWYsZOMSXph_r1pZvXgwVMV1PsWVc_bNK-AdkChf3vosne-Y7XvKO8oyCfNJdCxb3kPw9OtF6KVnPGL5irnA6WUiwGeNxdsR8Uo5HjZLPc_MOkjrsUZUnTaY3FhT-JMTPTHBT2GQkokPlo3n4h1GXXGOlxTLTpY4vwxxQckcS3Vgpm4QAKuKS5x74xeqjZYV1wM-UXzbNZLxpeP9br5_unj_c1te_f185ebD3etEQCl1ZTiWD-QRk9aI1opey4nZiZt-no69JMcYJyH2XJOjRRU7PRumBDmsae449fNm_PeetmvFXNR3mWDy6IDxjUrGAAGwfgIVcrOUpNizglndUzO63RSQNVGWR3URlltlBXlqlKupteP-9fJo_1r-YO1Ct6dBVi_fHCYVDYOg0HrEpqibHT_3__-H7tZXNhg_sQT5kOFHyo_BSozRdW3LectZuhrxIwB_w1wb6Ui</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Brennan, Faith H</creator><creator>Lee, John D</creator><creator>Ruitenberg, Marc J</creator><creator>Woodruff, Trent M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1382-911X</orcidid><orcidid>https://orcid.org/0000-0002-9201-2476</orcidid><orcidid>https://orcid.org/0000-0002-9976-7396</orcidid><orcidid>https://orcid.org/0000-0002-6917-0708</orcidid></search><sort><creationdate>20160601</creationdate><title>Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions</title><author>Brennan, Faith H ; Lee, John D ; Ruitenberg, Marc J ; Woodruff, Trent M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-a00e96185cabaaeed55635b2cbac627016b5819f8fd330c54047a78be1f960e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergy and Immunology</topic><topic>Brain - pathology</topic><topic>C5a</topic><topic>Clinical Trials as Topic</topic><topic>Complement</topic><topic>Complement Activation</topic><topic>Complement Inactivating Agents - therapeutic use</topic><topic>Complement System Proteins - metabolism</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative Diseases - immunology</topic><topic>Neurodegenerative Diseases - therapy</topic><topic>Neuroprotection</topic><topic>Neurotrauma</topic><topic>Stroke</topic><topic>Therapeutics</topic><topic>Treatment Outcome</topic><topic>Wounds and Injuries - immunology</topic><topic>Wounds and Injuries - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brennan, Faith H</creatorcontrib><creatorcontrib>Lee, John D</creatorcontrib><creatorcontrib>Ruitenberg, Marc J</creatorcontrib><creatorcontrib>Woodruff, Trent M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brennan, Faith H</au><au>Lee, John D</au><au>Ruitenberg, Marc J</au><au>Woodruff, Trent M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>28</volume><issue>3</issue><spage>292</spage><epage>308</epage><pages>292-308</pages><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>Highlights • Neurological diseases increasing in incidence but lack effective treatment. • Complement activation linked to the majority of neurological diseases. • Inhibition of complement generally protective in neurological disease models. • Therapies must balance protective and pathogenic sequela of complement activation. • Complement inhibitors show promise as future candidates for clinical trials.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27049459</pmid><doi>10.1016/j.smim.2016.03.015</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-1382-911X</orcidid><orcidid>https://orcid.org/0000-0002-9201-2476</orcidid><orcidid>https://orcid.org/0000-0002-9976-7396</orcidid><orcidid>https://orcid.org/0000-0002-6917-0708</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-5323 |
| ispartof | Seminars in immunology, 2016-06, Vol.28 (3), p.292-308 |
| issn | 1044-5323 1096-3618 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811842391 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergy and Immunology Brain - pathology C5a Clinical Trials as Topic Complement Complement Activation Complement Inactivating Agents - therapeutic use Complement System Proteins - metabolism Disease Progression Humans Molecular Targeted Therapy Neurodegeneration Neurodegenerative Diseases - immunology Neurodegenerative Diseases - therapy Neuroprotection Neurotrauma Stroke Therapeutics Treatment Outcome Wounds and Injuries - immunology Wounds and Injuries - therapy |
| title | Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A31%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20targeting%20of%20complement%20to%20modify%20disease%20course%20and%20improve%20outcomes%20in%20neurological%20conditions&rft.jtitle=Seminars%20in%20immunology&rft.au=Brennan,%20Faith%20H&rft.date=2016-06-01&rft.volume=28&rft.issue=3&rft.spage=292&rft.epage=308&rft.pages=292-308&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2016.03.015&rft_dat=%3Cproquest_cross%3E1811842391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811842391&rft_id=info:pmid/27049459&rft_els_id=1_s2_0_S1044532316000221&rfr_iscdi=true |